Y

esterday, we put out a list of the most overpaid pharma CEOs — those who got raises that far outpaced what they delivered to shareholders. But what about the execs who took pay cuts in the midst of business success?

Scouring the same data, gathered from 28 of the biggest pharma companies in the world, we found three CEOs who saw their compensation fall last year even though they made good money for investors.  They still pull in a lot of money. But compared to their peers, these three executives look underpaid.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy